Department of Pharmacology, University of California at San Diego, La Jolla, CA, USA.
Howard Hughes Medical Institute, University of California at San Diego, La Jolla, CA, USA.
Chem Biol Drug Des. 2018 Jan;91(1):5-16. doi: 10.1111/cbdd.13053. Epub 2017 Jul 19.
The A adenosine receptor (A AR) is a G protein-coupled receptor that is pharmacologically targeted for the treatment of inflammation, sepsis, cancer, neurodegeneration, and Parkinson's disease. Recently, we applied long-timescale molecular dynamics simulations on two ligand-free receptor conformations, starting from the agonist-bound (PDB ID: 3QAK) and antagonist-bound (PDB ID: 3EML) X-ray structures. This analysis revealed four distinct conformers of the A AR: the active, intermediate 1, intermediate 2, and inactive. In this study, we apply the fragment-based mapping algorithm, FTMap, on these receptor conformations to uncover five non-orthosteric sites on the A AR. Two sites that are identified in the active conformation are located in the intracellular region of the transmembrane helices (TM) 3/TM4 and the G protein-binding site in the intracellular region between TM2/TM3/TM6/TM7. Three sites are identified in the intermediate 1 and intermediate 2 conformations, annexing a site in the lipid interface of TM5/TM6. Five sites are identified in the inactive conformation, comprising a site in the intracellular region of TM1/TM7 and in the extracellular region of TM3/TM4 of the A AR. We postulate that these sites on the A AR be screened for allosteric modulators for the treatment of inflammatory and neurological diseases.
A 腺苷受体(A AR)是一种 G 蛋白偶联受体,可通过药理学靶向治疗炎症、败血症、癌症、神经退行性疾病和帕金森病。最近,我们应用长时程分子动力学模拟方法,对两种无配体的受体构象进行了研究,这两种构象分别来自激动剂结合(PDB ID:3QAK)和拮抗剂结合(PDB ID:3EML)的 X 射线结构。该分析揭示了 A AR 的四种不同构象:激活、中间态 1、中间态 2 和无活性。在这项研究中,我们应用基于片段的映射算法 FTMap,对这些受体构象进行了分析,以揭示 A AR 上的五个非经典结合位点。在激活构象中鉴定出的两个位点位于跨膜螺旋(TM)3/TM4 的细胞内区域和细胞内 TM2/TM3/TM6/TM7 之间的 G 蛋白结合位点。在中间态 1 和中间态 2 构象中鉴定出三个位点,这些位点位于 TM5/TM6 的脂质界面上。在无活性构象中鉴定出五个位点,包括 TM1/TM7 的细胞内区域和 A AR 的 TM3/TM4 的细胞外区域的一个位点。我们推测,这些 A AR 上的位点可以被筛选出用于治疗炎症和神经退行性疾病的变构调节剂。